Synthetic Genomics Asset Acquisition (Details) - USD ($)			1 Months Ended	3 Months Ended			6 Months Ended
	Dec. 20, 2018	Feb. 28, 2018	Feb. 28, 2018	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest expense				$ 0		$ 142,000	$ 62,000	$ 301,000
Synthetic Genomics Inc [Member] | C3J [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid for productive assets		$ 8,000,000.0	$ 8,000,000.0
Cash paid acquisition of assets		1,000,000.0			$ 2,000,000.0
Issuance of common stock and conversion of deferred consideration for asset acquisition		27,000,000.0
Percentage of fully diluted capitalized for issuance of common stock			10.00%
Maximum potential milestone payments			$ 39,500,000
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets		1,000,000.0
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment Two [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets		1,000,000.0
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment Three [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets		1,000,000.0
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment Four [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets		$ 5,000,000.0
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Amended Expected Payment One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets	$ 1,000,000.0
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Amended Expected Payment Two [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets	1,000,000.0
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Amended Expected Payment Three [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets	$ 2,000,000.0